Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncodesign Precision Medicine (FRA:ZR8) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Oncodesign Precision Medicine's Enterprise Value for the quarter that ended in Dec. 2025 was €10.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncodesign Precision Medicine's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €5.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine EV-to-EBIT Related Terms
Oncodesign Precision Medicine EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ZR8 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Oncodesign Precision Medicine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncodesign Precision Medicine EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Oncodesign Precision Medicine's EV-to-EBIT falls into.
Oncodesign Precision Medicine's current Enterprise Value is €10.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncodesign Precision Medicine's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €5.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine (FRA:ZR8) has a EV-to-EBIT of 1.81 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oncodesign Precision Medicine and its competitors. According to the industry distribution chart, Oncodesign Precision Medicine ranks #87 out of 380 companies in the Biotechnology industry, placing it in the top 22.9%.
Is Oncodesign Precision Medicine's EV-to-EBIT too high?
Oncodesign Precision Medicine's current EV-to-EBIT is 1.81. The Biotechnology industry median EV-to-EBIT is 15.92. Oncodesign Precision Medicine's value of 1.81 is 88.6% below this industry median. Based on the distribution chart, Oncodesign Precision Medicine ranks #87 out of 380 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncodesign Precision Medicine has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncodesign Precision Medicine ranks #87 out of 380 companies for EV-to-EBIT. This places Oncodesign Precision Medicine in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.92. Oncodesign Precision Medicine's value of 1.81 is 88.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.92, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncodesign Precision Medicine's current EV-to-EBIT of 1.81 is 88.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oncodesign Precision Medicine and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncodesign Precision Medicine's current EV-to-EBIT is 1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Oncodesign Precision Medicine (FRA:ZR8) has a current EV-to-EBIT of 1.81. The stock's GF Value™ is €0.27, compared to a current price of €0.29 — trading 7% above its estimated fair value. The current EV-to-EBIT is 1.81 and 88.6% below the Biotechnology industry median of 15.92. Oncodesign Precision Medicine's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current EV-to-EBIT is 1.81 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?
Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued.
The current stock price of €0.29 is trading 7% above its estimated GF Value™ of €0.27.
Key valuation signals for FRA:ZR8:
EV-to-EBIT: 1.81
GF Value™: €0.27 vs. price of €0.29 (7% above fair value)
Industry Position: 88.6% below the Biotechnology median (#87 of 380)
No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
34GF Score
Get the complete analysis for FRA:ZR8
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZR8 has been successfully added to your 
